|
1.
|
|
9 p, 902.3 KB |
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients : an exploratory longitudinal study
/
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Garcia-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ;
Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
De-Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Lianes, Piar (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Remon, Jordi (CIOCC Barcelona - HM Delfos) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Universitat Autònoma de Barcelona
Little is known about the impact of sex on lung cancer patients from the psychological, economic and social perspectives. This study was designed to explore the psychosocial and economic impact according to sex of metastatic non-small cell lung cancer (mNSCLC) in patients and caregivers. [...]
2020 -  10.1186/s40359-020-00489-z
BMC Psychology, Vol. 8 Núm. 1 (december 2020) , p. 123
|
|
|
2.
|
|
11 p, 421.8 KB |
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ;
John, Thomas (Department of Medical Oncology. Austin Health) ;
Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ;
Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ;
Kim, Sang-We (Department of Oncology. Asan Medical Center) ;
Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ;
Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ;
Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ;
Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ;
Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ;
Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ;
Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ;
Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ;
Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ;
Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ;
Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ;
Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296
|
|
|
3.
|
|
17 p, 534.5 KB |
COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
/
Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Barlesi, Fabrice (Gustave Roussy) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Chu, Quincy (Cross Cancer Institute) ;
Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ;
Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ;
Dakhil, Shaker (Cancer Center of Kansas) ;
Camidge, D (University of Colorado Anschutz Medical Campus) ;
Winzer, Leanne (AstraZeneca) ;
Soo-Hoo, Yee (AstraZeneca) ;
Cooper, Zachary A. (AstraZeneca) ;
Kumar, Rakesh (AstraZeneca) ;
Bothos, John (AstraZeneca) ;
Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227
|
|
|
4.
|
|
12 p, 923.8 KB |
Small Cell Carcinoma of the Vagina : First Systematic Review of Case Reports and Proposal of a Management Algorithm
/
Capote, Sira (Fundació Hospital de l'Esperit Sant) ;
Domènech, Marta (Institut Català d'Oncologia) ;
Valdivieso, Lorena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tuset, Victoria (Institut Català d'Oncologia) ;
Sanchez, Myriam (Fundació Hospital de l'Esperit Sant) ;
Carballas, Elvira (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teruel, Iris (Institut Català d'Oncologia) ;
Durany Lara, David (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Moragas, Gloria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina, Carlos (Fundació Hospital de l'Esperit Sant) ;
Lleberia, Judith (Fundació Hospital de l'Esperit Sant) ;
Martínez-Roman, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Romeo, Margarita (Institut Català d'Oncologia) ;
Universitat Autònoma de Barcelona
Literature search in PubMed and Scopus was performed using the terms "small cell carcinoma" and "vagina. " English-language case reports of primary SmCCV up to January 2022 were included. Twenty-nine articles describing 44 cases met our inclusion criteria. [...]
2022 - 10.1097/LGT.0000000000000712
Journal of Lower Genital Tract Disease, Vol. 27 (october 2022) , p. 56-67
|
|
|
5.
|
|
37 p, 420.1 KB |
Cabozantinib combination therapy for the treatment of solid tumors : a systematic review
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari 'Aldo Moro') ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas) ;
Martin, Lidia (Ipsen Pharma) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. [...]
2022 - 10.1177/17588359221108691
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
6.
|
|
18 p, 1.7 MB |
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma : A Systematic Review and Meta-Analysis
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
González-Cao, María (Hospital Dexeus) ;
Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Instituto de Investigación Biomédica de Málaga) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña) ;
Crama, Leonardo (Medical Department Roche) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. [...]
2022 - 10.1007/s40487-021-00182-0
Oncology and Therapy, Vol. 10 Núm. 1 (june 2022) , p. 167-184
|
|
|
7.
|
|
11 p, 555.4 KB |
LungBEAM : A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
/
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
Paz-Ares, Luis (Universidad Complutense de Madrid) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Garcίa-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Viñolas, Núria (Hospital Clínic i Provincial de Barcelona) ;
Camps, Carlos (Hospital General Universitario de Valencia) ;
Insa, Amelia (Hospital Clínico Universitario) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron)
Objectives: The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). [...]
2021 - 10.1002/cam4.4135
Cancer Medicine, Vol. 10 Núm. 17 (september 2021) , p. 5878-5888
|
|
|
8.
|
|
15 p, 2.0 MB |
Epigenome-wide three-way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early-stage NSCLC
/
Ji, Xinyu (Nanjing Medical University) ;
Lin, Lijuan (Nanjing Medical University) ;
Fan, Juanjuan (Nanjing Medical University) ;
Li, Yi (University of Michigan) ;
Wei, Yongyue (Nanjing Medical University) ;
Shen, Sipeng (Nanjing Medical University) ;
Su, Li (Harvard T.H. Chan School of Public Health (Estats Units d'Amèrica)) ;
Shafer, Andrea (Harvard Medical School) ;
Bjaanæs, Maria Moksnes (Oslo University Hospital (Oslo, Noruega)) ;
Karlsson, Anna (Lund University) ;
Planck, Maria (Lund University) ;
Staaf, Johan (Lund University) ;
Helland, Åslaug (University of Oslo) ;
Esteller, M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zhang, Ruyang (Nanjing Medical University) ;
Chen, Feng (Nanjing Medical University) ;
Christiani, David C (Harvard Medical School) ;
Universitat Autònoma de Barcelona
The interaction between DNA methylation of tripartite motif containing 27 (cg05293407) and smoking has previously been identified to reveal histologically heterogeneous effects of TRIM27 DNA methylation on early-stage non-small-cell lung cancer (NSCLC) survival. [...]
2022 - 10.1002/1878-0261.13167
Molecular Oncology, Vol. 16 Núm. 3 (february 2022) , p. 717-731
|
|
|
9.
|
|
13 p, 941.6 KB |
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
/
Casarrubios, Marta (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Cruz-Bermúdez, Alberto (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Nadal, Ernest (Institut Català d'Oncologia) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
García Campelo, María del Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Lázaro, Martín (Hospital Universitario de Vigo) ;
Dómine Gómez, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Del Barco Morillo, Edel (Hospital Universitario de Salamanca) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Quiron Dexeus) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Barquín, Miguel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Laza-Briviesca, Raquel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Sierra-Rodero, Belén (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ;
Parra, Edwin R. (The University of Texas. Department of Translational Molecular Pathology) ;
Sanchez-Espiridion, Beatriz (The University of Texas. Department of Translational Molecular Pathology) ;
Rocha, Pedro (The University of Texas. Department of Translational Molecular Pathology) ;
Kadara, Humam (The University of Texas. Department of Translational Molecular Pathology) ;
Wistuba, Ignacio I. (The University of Texas. Department of Translational Molecular Pathology) ;
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). [...]
2021 - 10.1158/1078-0432.CCR-21-1200
Clinical Cancer Research, Vol. 27 Núm. 21 (November 2021) , p. 5878-5890
|
|
|
10.
|
|
8 p, 738.7 KB |
Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation
/
Konstantinidis Garay, Cristián (Universitat Autònoma de Barcelona) ;
Trilla Herrera, Enrique (Universitat Autònoma de Barcelona) ;
Serres-Créixams, Xavier (Hospital Universitari Vall d'Hebron) ;
Montealegre, Carolina (Hospital Universitari Vall d'Hebron) ;
Lorente, David (Universitat Autònoma de Barcelona) ;
Castellón, Rafael (Hospital Universitari Vall d'Hebron) ;
Morote Robles, Juan (Universitat Autònoma de Barcelona)
An association between the R. E. N. A. L. nephrometry score (RNS) and clinical outcomes in patients with a small renal mass (SRM) has been proposed. We analyzed clinical outcomes according to the RNS in patients with a SRM treated with percutaneous contrast enhanced ultrasound (CEUS) radiofrequency ablation (RFA). [...]
2019 - 10.5173/ceju.2019.1833
Central European Journal of Urology, Vol. 72 (june 2019) , p. 92-99
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
